<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03301870</url>
  </required_header>
  <id_info>
    <org_study_id>ATx201-006</org_study_id>
    <nct_id>NCT03301870</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Irritation Potential of ATx201 in Healthy Volunteers</brief_title>
  <official_title>A Single-Site Study To Evaluate The Irritation Potential Of Topically Applied ATx201 In Healthy Human Volunteers on Intact and Abraded Skin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNION therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNION therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I single-site study to evaluate the irritation potential of topically applied&#xD;
      ATx201 GEL, 2% and 4%, along with positive and negative control and placebo control (ATx201&#xD;
      GEL Placebo), in healthy human subjects on intact and abraded skin. Approximately thirty-six&#xD;
      (36) healthy adult subjects will receive all the test articles to provide for 30 subjects to&#xD;
      complete the study. The test articles will be applied to the upper back of the subjects&#xD;
      during the study, and the placement of the test articles will be randomized. Abraded skin&#xD;
      will be induced using sequential tape stripping.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 4, 2017</start_date>
  <completion_date type="Actual">November 6, 2017</completion_date>
  <primary_completion_date type="Actual">November 6, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>the assignment of the test articles to the test sites will be randomized. Each &quot;arm&quot; is a different patch of skin on the same study participant</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Irritation Scores</measure>
    <time_frame>21 days</time_frame>
    <description>the sum of the combined Dermal response and Other Effects Score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of combined Dermal response and Other Effects Score &gt;=3</measure>
    <time_frame>21 days</time_frame>
    <description>Total number of days with a combined Dermal Response and Other Effects score of 3 or more for each test article</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Test Article Discontunation</measure>
    <time_frame>21 days</time_frame>
    <description>Number of subjects, by test article, where a test article was discontinued due to an unacceptable degree of irritation, or who experienced symptomatic intolerable irritation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to test article discontinuation</measure>
    <time_frame>21 days</time_frame>
    <description>Number of days until sufficient irritation occurred to preclude repeat application to the same site, or who experienced symptomatic intolerable irritation</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Irritation Potential of Topic Agent</condition>
  <arm_group>
    <arm_group_label>ATx201 GEL, 2% - intact skin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATx201 GEL, 2% applied intact skin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATx201 GEL, 4% - intact skin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATx201 GEL, 4% applied to intact skin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATx201 GEL, 2% - abraded skin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATx201 GEL, 2% applied to abraded skin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATx201 GEL, 4% - abraded skin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATx201 GEL, 4% applied to abraded skin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATx201 GEL Placebo - intact skin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ATx201 GEL Placebo applied to intact skin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATx201 GEL Placebo - abraded skin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ATx201 GEL Placebo applied to abraded skin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative Irritant Control - intact skin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Negative (low) Irritant Control applied to intact skin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative Irritant Control - abraded skin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Negative (low) Irritant Control applied to abraded skin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive Irritant Control - intact skin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Positive (high) Irritant Control applied to intact skin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATx201 Gel 2%</intervention_name>
    <description>2% active gel</description>
    <arm_group_label>ATx201 GEL, 2% - abraded skin</arm_group_label>
    <arm_group_label>ATx201 GEL, 2% - intact skin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATx201 Gel 4%</intervention_name>
    <description>4% active gel</description>
    <arm_group_label>ATx201 GEL, 4% - abraded skin</arm_group_label>
    <arm_group_label>ATx201 GEL, 4% - intact skin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Positive Control</intervention_name>
    <description>Sodium Lauryl Sulfate 0.05% (w/v), USP in sterile, distilled Water for Injection, USP</description>
    <arm_group_label>Positive Irritant Control - intact skin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Negative Control</intervention_name>
    <description>Water for Injection, USP</description>
    <arm_group_label>Negative Irritant Control - abraded skin</arm_group_label>
    <arm_group_label>Negative Irritant Control - intact skin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATx201 Placebo</intervention_name>
    <description>matching placebo gel</description>
    <arm_group_label>ATx201 GEL Placebo - abraded skin</arm_group_label>
    <arm_group_label>ATx201 GEL Placebo - intact skin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Judged by the Investigator to have no health conditions that would impact the safety&#xD;
             of the subject during participation.&#xD;
&#xD;
          -  Body Mass Index (BMI) to be no less than 19.0 and no greater than 36.0 kg/mÂ²&#xD;
             (inclusive).&#xD;
&#xD;
          -  Demonstrates a Fitzpatrick skin score of I - IV&#xD;
&#xD;
          -  Female subjects must agree to use a medically acceptable contraceptive method&#xD;
&#xD;
          -  Willing to refrain from excessive consumption of sodium (&gt; 2,400 mg/day or &gt; 1&#xD;
             teaspoon equivalent/day) in food or beverage 48 hours prior to Day 1 through EOS&#xD;
             Visit.&#xD;
&#xD;
          -  Willing to shower using the same non-medicated soap/cleansers, and abstain from&#xD;
             excessive sun exposure (including tanning salons) from the Screening Visit through EOS&#xD;
             Visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  any clinical investigational product within 30 days prior to Day 1 through EOS Visit&#xD;
&#xD;
          -  recent or current medical condition that, in the opinion of the Investigator, might&#xD;
             significantly affect an immunological response to topical ATx201 or compromise the&#xD;
             safety of the subject.&#xD;
&#xD;
          -  history of diabetes mellitus, clinically significant asthma (acceptable if no episode&#xD;
             within 5 years prior to Day 1), or currently diagnosed with hypertension or&#xD;
             circulatory disease.&#xD;
&#xD;
          -  use of any medication on a regular basis within 14 days prior to Day 1 through EOS&#xD;
             that could change peripheral blood flow, with the exception of any prescribed birth&#xD;
             control method or hormone replacement therapy.&#xD;
&#xD;
          -  use of any oral, nasal or topical corticosteroids, or oral or topical retinoids (other&#xD;
             than Vitamin A at normal dietary amounts) within 14 days prior to the Screening Visit&#xD;
             through EOS Visit.&#xD;
&#xD;
          -  intending to start, stop, or change the dose of any prescription or over-the-counter&#xD;
             (OTC) medication within 48 hours prior to Day 1 through EOS Visit.&#xD;
&#xD;
          -  use of any prescription or OTC topical medications on the upper back within 30 days&#xD;
             prior to Day 1 through EOS Visit.&#xD;
&#xD;
          -  history of sensitivity/allergy to any ingredients found in the ATx201 formulation or&#xD;
             has a history of adverse reactions to topical medications.&#xD;
&#xD;
          -  significant history of allergy to soaps, lotions, emollients, ointments, creams,&#xD;
             cosmetics, adhesives, or latex.&#xD;
&#xD;
          -  history of significant skin conditions or disorders such as psoriasis, atopic&#xD;
             dermatitis, etc.&#xD;
&#xD;
          -  history of significant dermatologic cancers, for example, melanoma or squamous cell&#xD;
             carcinoma.&#xD;
&#xD;
          -  displays an obvious difference in skin color on the upper back or the presence of a&#xD;
             skin anomaly such as a recent sunburn, scratch, scar tissue, tattoo, or coloration&#xD;
             that would interfere with placement of test sites, their assessment, and their&#xD;
             potential response to the study drug or that could compromise the safety of the&#xD;
             subject.&#xD;
&#xD;
          -  smoking or use of tobacco or nicotine delivery products within 14 days prior to Day 1&#xD;
             through EOS Visit.&#xD;
&#xD;
          -  female who is pregnant, lactating, breastfeeding, or intends to become pregnant over&#xD;
             the course of the study.&#xD;
&#xD;
          -  history of drug or alcohol addiction or abuse within the past year.&#xD;
&#xD;
          -  caffeine intake greater than 500 mg per day (for example, 1 cup of coffee contains&#xD;
             approximately 85 mg of caffeine, tea approximately 25 mg, soft drinks up to 115 mg,&#xD;
             energy drinks 90 - 422 mg).&#xD;
&#xD;
          -  unwilling to abstain from energy drinks, alcohol, and excessive caffeine (&gt; 500&#xD;
             mg/day) for 48 hours prior to Day 1 through EOS Visit.&#xD;
&#xD;
          -  reports having donated blood or plasma within 48 hours prior to Day 1 through EOS&#xD;
             Visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Prokocimer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor CMO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bio-Kinetic Clinical Applications, LLC</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>September 29, 2017</study_first_submitted>
  <study_first_submitted_qc>September 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2017</study_first_posted>
  <last_update_submitted>January 14, 2019</last_update_submitted>
  <last_update_submitted_qc>January 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

